Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | $18.00 | Mkt Outperform | JMP Securities |
| 8/28/2024 | $30.00 | Outperform | Oppenheimer |
| 4/22/2024 | $30.00 | Overweight | Wells Fargo |
| 4/15/2024 | $34.00 | Buy | Guggenheim |
| 3/28/2024 | $37.00 | Buy | UBS |
| 3/8/2024 | $40.00 | Overweight | Morgan Stanley |
| 2/20/2024 | $31.00 | Outperform | Leerink Partners |
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chief Technology Officer (CTO) and member of the corporate leadership team. In addition, enGene Co-Founder and former CTO, Anthony Cheung, Ph.D., will transition to the role of Chief Scientific Officer, succeeding James Sullivan, MSc, Ph.D. Ms. Connolly's career spans
Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced succession plan for Jason Hanson, who will remain in service to the Company as a strategi
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
JMP Securities initiated coverage of enGene Holdings with a rating of Mkt Outperform and set a new price target of $18.00
Oppenheimer initiated coverage of enGene Holdings with a rating of Outperform and set a new price target of $30.00
Wells Fargo initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $30.00
Data from pivotal cohort demonstrate compelling clinical activity, consistent with Phase 1 results Favorable tolerability profile with no drug-related discontinuations Detalimogene's profile to date supports its potential as a foundational therapy for NMIBC enGene to host a conference call to discuss preliminary data today at 8:00 a.m. ET enGene Holdings Inc. (NASDAQ:ENGN), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with
Company remains on track to report preliminary LEGEND data in September 2024 Cash and cash equivalents of $257.7 million provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), announced its financial results for the third quarter ended July 31, 2024 and provided a business update. "Detalimogene was designed to be
Company announces plans for initial indication expansion for EG-70 into high-risk papillary-only NMIBC enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the second quarter ended April 30, 2024, and provided a business update. "Our $200 million private placement in February positioned us well to execute our primary strategy of broadly developing EG-70 to be a patient- and practice-friendly option across a multitude of potential bladde
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
EFFECT - enGene Holdings Inc. (0001980845) (Filer)
EFFECT - enGene Holdings Inc. (0001980845) (Filer)
424B3 - enGene Holdings Inc. (0001980845) (Filer)
Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer
EnGene Holdings Inc. (NASDAQ:ENGN) shares are trading lower Friday after the company, reported its financial results for the second quarter. What To Know: EnGene Holdings announced a net loss of $15.0 million, or $0.38 per share, compared to a loss of $6.5 million, or $9.30 per share, for the same period in 2023, according to Benzinga Pro. This increase in net loss is primarily due to higher operating expenses, which rose from $4.7 million to $17.3 million year-over-year, driven by increased research and development costs and administrative expenses as the company scales its operations. What Else: In addition to financial updates, EnGene highlighted strategic developments, including th
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Officer, and Raj Pruthi, M.D., Chief Medical Officer, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 10:30 a.m. ET. A live webcast of the fireside chat can be accessed under the "Investors" s
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of its common shares at a price per share of $8.90. The financing is expected to close on October 29, 2024, subject to customary closing conditions. enGene anticipates the gross proceeds from the private placement to be approximately $60 million, before deducting any o
enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of an inducement equity award to Joan Connolly, the Company's newly-appointed Chief Technology Officer, with a grant date of October 21, 2024. The inducement award consists of a non-qualified stock option to purchase an aggregate 210,000 of the Company's common sha
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)